New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
08:31 EDTNVAXNovavax says BARDA continues contract for both seasonal, pandemic flu programs
Novavax announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority, or BARDA, has completed an In-Process Review of Novavax' contract covering the company's recombinant virus-like particle vaccine candidates for pandemic and seasonal influenza. The contractually-defined IPR was conducted by a team of U.S. Government experts, who provided input on Novavax' progress during the contract base period and plans for further development, including both near-term process development and manufacturing activities and longer-term clinical efforts. BARDA has notified the company that based on the results of the IPR, a milestone decision has been made to continue the contract for both the seasonal and pandemic influenza programs. In March 2011, Novavax was awarded a contract valued at up to $179M by BARDA for the advanced development of recombinant vaccines for the prevention of seasonal and pandemic influenza. In the midst of the contract's 3-year base period, valued at $97M, Novavax has been developing and testing its novel recombinant virus-like particle influenza vaccines to address BARDA's commitment to advancing recombinant-based technology as a component of pandemic preparedness. The contract can be extended for an additional 24-month option period at BARDA's option, with $82M in additional funding to build on the work Novavax accomplishes during the base period and to support manufacturing scale-up and licensure by the U.S. Food & Drug Administration.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:14 EDTNVAXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Visa (V), up 4%... MasterCard (MA), up 2.5%... Alcatel-Lucent (ALU), up 12.5%... TASER (TASR), up 4%... JDSU (JDSU), up 3.8%... Radian Group (RDN), up 9%... DreamWorks Animation (DWA), up 1.7%... Take-Two (TTWO), up 7.7%. ALSO HIGHER: Grand Canyon (LOPE), up 10.5%, upgraded at Piper Jaffray after the company formed a committee to explore conversion to a nonprofit entity... Walter Energy (WLT), up 6.8% after lowering FY14 capital expenditures view, reporting lower than expected losses... Novavax (NVAX), up 7% after getting fast track designation for H7N9 VLP. DOWN AFTER EARNINGS: Glu Mobile (GLUU), down 16.6%... Alliance Fiber Optic (AFOP), down 18.4%... Pacira (PCRX), down 6.4%. ALSO LOWER: Sturm, Ruger (RGR), down 10% following Q3 results, cutting Q3 dividend. Peer gunmaker Smith & Wesson (SWHC) also down 3.7% after Ruger's report... Western Gas Partners (WES), down 4.4% after its 7.5M common units spot secondary priced at $70.85... ACCO Brands (ACCO), down 1.1%, downgraded at KeyBanc following the company's Q3 results... Fiat Chrysler (FCAU), down 1.1% after reported to be recalling over 300K Ram trucks due to fire concern... Inogen (INGN), down 2.3% after 2.1M share secondary offering of common stock priced at $21.50.
October 29, 2014
18:59 EDTNVAXOn The Fly: After Hours Movers
Subscribe for More Information
17:21 EDTNVAXNovavax gets fast track designation for H7N9 VLP
Novavax announced that the U.S. Food and Drug Administratio has granted Fast Track Designation to Novavax' H7N9 Virus-Like Particle Vaccine Candidate adjuvanted with Matrix-Mô. The H7N9 VLP is being developed under the company's contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority,BARDA, for the development of Novavax' recombinant vaccines to address seasonal influenza and influenza strains with pandemic potential. "The FDA's Fast Track Designation for our H7N9 VLP underscores the FDA's recognition of the risk of H7N9 influenza, the lack of any approved vaccines for H7N9 influenza, and the strength of our H7N9 VLP," said Stanley C. Erck, President and CEO of Novavax. "This achievement is another example of the capabilities of our technology platform, the commitment of our people, and the importance of our collaboration with BARDA."
October 27, 2014
16:36 EDTNVAXOn The Fly: Closing Wrap
Subscribe for More Information
11:24 EDTNVAXNovavax rises after announcing Ebola vaccine development program
Subscribe for More Information
09:14 EDTNVAXOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTNVAXNovavax announces Ebola vaccine development program
Subscribe for More Information
October 26, 2014
12:58 EDTNVAXNovavax presents RSV F protein nanoparticle vaccine clinical data
Novavax announced that Gregory Glenn, M.D., SVP, Research and Development is presenting new immunogenicity data from Novavax' RSV F-Protein Nanoparticle vaccine candidate, RSV F vaccine, clinical trials at the 8th Vaccine & ISV Congress in Philadelphia.
October 17, 2014
08:28 EDTNVAXNovavax management to meet with JPMorgan
Subscribe for More Information
October 16, 2014
11:15 EDTNVAXHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use